Active ingredient
Registrations named Rivaroxaban
Rivaroxaban is an active ingredient, not a brand name. 6 registrations in the DRAP register carry it in the product name, and the price index attributes them to 1 manufacturer — these are generic products, not one company's range.
- Registrations
- 6
- Manufacturers
- 1
- Dosage forms
- Tablet
- Approved price range
- Rs 8,245.85 – Rs 11,545.41
Registrations
| Registered name | Reg. No. | Strength | Form | Manufacturer | Price from |
|---|---|---|---|---|---|
| Rivaroxaban 20 mg Tablet | 008045-EX | 20 mg | Tablet | — | — |
| Rivaroxaban 20mg Tablet | 112892 | 20mg | Tablet | Pacific Pharmaceuticals Ltd. | Rs 8,245.85 |
| Rivaroxaban Tablet 10mg | 108611 | 10mg | Tablet | — | — |
| Rivaroxaban Tablet 15mg | 108613 | 15mg | Tablet | — | — |
| Rivaroxaban Tablet 2.5mg | 114451 | 2.5mg | Tablet | — | — |
| Rivaroxaban Tablet 20mg | 108612 | 20mg | Tablet | — | — |
Why this is not described as a brand
The DRAP register has no separate brand column, so an ingredient name and a trade name look identical in the data. This group is an ingredient: the products below are made by different companies under their own trade names, and no single company owns the word.
How these are grouped
These registrations are grouped by the words in their registered name. Strength, pack size, dosage form and trailing variant words such as Forte, Extra, CF, DS and XR are removed before grouping, so Panadol Tablet, Panadol CF Tablet and Panadol Extra Tablet count as one group. Names that only share a first word but mean different things — for example two companies' unrelated products — can still land together; the registered name of every row is shown so the grouping is checkable.
Source: the bundled DRAP registered-products index and the DRAP price index. Prices are regulatory listings, not pharmacy stock or a retail quote.